Fidia S.p.A. (BIT:FDA)
Italy · Delayed Price · Currency is EUR | Market Cap | 317.37K -34.9% |
| Revenue (ttm) | 21.13M -28.9% |
| Net Income | -2.19M |
| EPS | -1.15 |
| Shares Out | 14.90M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 3,020,669 |
| Average Volume | 2,354,256 |
| Open | 0.0228 |
| Previous Close | 0.0220 |
| Day's Range | 0.0200 - 0.0228 |
| 52-Week Range | 0.0200 - 0.9600 |
| Beta | 0.03 |
| RSI | 6.60 |
| Earnings Date | Apr 28, 2026 |
About Fidia
Fidia S.p.A., together with its subsidiaries, designs, manufactures, and sells high speed milling systems, numerical controls, milling heads, and software systems. The company offers HMS, a device for measuring and compensating geometric error on continuous or indexed bi-rotary heads and roto-tilting tables; TMSC, a device to measure length and diameter of the tool, as well as to check the shape; pushbutton panels; XPower digital drives for axis and spindle movement; and I/O Line input/output modules. It also provides software solutions include... [Read more]
Financial Performance
In 2024, Fidia's revenue was 17.53 million, a decrease of -38.98% compared to the previous year's 28.74 million. Losses were -9.30 million, 611.4% more than in 2023.
Financial StatementsNews
Why Milestone Pharma Stock Is Taking A Dive Today
Milestone Pharmaceuticals Inc. (NASDAQ: MIST) shares are tumbling on Friday after the company revealed a minor pushback in European approval for its lead drug . • Milestone Pharmaceuticals stock is t...
Children's ibuprofen recall: FDA issues notice for Taro Pharmaceuticals' product
Nearly 90,000 bottles of a children’s pain reliever have been recalled due to reports of particles and other possible contaminants.
Novo Nordisk Expands Obesity Drug Offerings with FDA Approval
Novo Nordisk Expands Obesity Drug Offerings with FDA Approval
Palatin's Case Strengthens as Rhythm's FDA Approval Validates Hypothalamic Obesity Market (PTN)
Palatin's Case Strengthens as Rhythm's FDA Approval Validates Hypothalamic Obesity Market (PTN)
Weekly Buzz: GSK's Lynavoy Gets FDA Nod; Reproxalap Rejected Again; LNSR Ends Merger Deal
(RTTNews) - This week's biotech landscape witnessed key FDA approvals, rejections, NDA resubmissions, merger terminations, trial discontinuations, and clinical trial data readouts across therapeutic a...
Rhythm Pharma Wins FDA Approval For First-Ever Rare Weight Disorder Therapy
The U.S. Food and Drug Administration (FDA) on Thursday approved an expanded indication for Rhythm Pharmaceuticals Inc.’s (NASDAQ: RYTM) Imcivree (setmelanotide) to treat acquired hypothalamic obesit...
Rhythm Surges On A New Obesity Approval; How It Edged In Where Lilly, Novo 'Have Fallen Flat'
Rhythm Pharmaceuticals stock popped Friday after the FDA signed off on its obesity drug for patients with a rare, hunger-spiking disease.
Aquestive Therapeutics Announces New Role of Lori J. Braender and Appointment of Thomas A. Zalewski as Chief Legal Officer and Chief Compliance Officer
Thomas A. Zalewski, a Partner at Day Pitney LLP, appointed Chief Legal Officer and Chief Compliance Officer effective April 2, 2026 Lori J. Braender to remain in a non-executive role as Corporate Secr...
Novo Nordisk Wins FDA Approval For Higher-Dose Wegovy HD, Delivering 20.7% Weight Loss
(RTTNews) - Novo Nordisk (NVO) announced that the FDA has approved Wegovy HD (semaglutide 7.2 mg), a higher-dose, once-weekly injectable version of its blockbuster obesity drug Wegovy, offering patien...
Rhythm Secures FDA Approval For IMCIVREE In Acquired Hypothalamic Obesity
(RTTNews) - Rhythm Pharmaceuticals, Inc. (RYTM) announced that the FDA has approved IMCIVREE for the treatment of acquired hypothalamic obesity, marking the first and only therapy cleared for this rar...
Novo Nordisk (NVO) Gains FDA Approval for New High-Dose Wegovy
Novo Nordisk (NVO) Gains FDA Approval for New High-Dose Wegovy
FDA approves higher dose of Wegovy
The Food and Drug Administration (FDA) on Thursday approved a higher dose of the Wegovy weight loss drug. The manufacturer, Novo Nordisk, increased the semaglutide injection by 4.8 mg to total 7.2 mg....
FDA approves high-dose Wegovy shots
U.S. regulators on Thursday approved a new higher-dose version of the blockbuster obesity drug Wegovy.
Novo Nordisk Secures FDA Approval For Higher-Dose Wegovy
The U.S. Food and Drug Administration (FDA) on Thursday approved a higher-dose version of Novo Nordisk A/S’ (NYSE: NVO) blockbuster weight-loss drug, Wegovy, marking an expansion of its treatment por...
Novo Nordisk (NVO) Gains FDA Approval for New Weight Loss Drug
Novo Nordisk (NVO) Gains FDA Approval for New Weight Loss Drug
FDA Flags Safety Concern Over Intuitive Surgical Stapler
The U.S. Food and Drug Administration (FDA) on Wednesday issued an early alert highlighting a potentially high-risk issue with stapling devices manufactured by Intuitive Surgical, Inc . (NASDAQ: ISRG ...
FDA approves higher dose version of weight loss drug Wegovy as Novo Nordisk tries to win back market share
The high-dose Wegovy helped patients with obesity lose an average 20.7% of their weight after 72 weeks in a phase three trial.
FDA approves Novo Nordisk's new Wegovy® HD injection, delivering the highest weight loss to date for a Wegovy® injection, adding to its already expansive clinical profile
Average weight loss of ~21% at 72 weeks in adults with obesity if all patients stayed on treatment * with Wegovy ® HD (~19% regardless of whether patients stayed on treatment **) in the STEP UP trial...
Sarepta To Request FDA For Traditional Approvals For Duchenne Drugs
Sarepta Therapeutics Inc. (NASDAQ: SRPT) shares are down during Thursday’s session following a regulatory update regarding its treatments for Duchenne muscular dystrophy . Sarepta Seeks Regular FDA A...
LivaNova (LIVN) Receives FDA Approval for Aura6000 Sleep Apnea System
LivaNova (LIVN) Receives FDA Approval for Aura6000 Sleep Apnea System
Merck (MRK) Gains FDA Approval for Expanded Bravecto Quantum Use
Merck (MRK) Gains FDA Approval for Expanded Bravecto Quantum Use
GSK Secures FDA Approval for Lynavoy in Treating PBC-Related Itch
GSK Secures FDA Approval for Lynavoy in Treating PBC-Related Itch
What's Going On With Aldeyra Therapeutics Stock On Thursday?
Aldeyra Therapeutics Inc. (NASDAQ: ALDX) shares are down during Thursday’s premarket session following the company’s recent challenges with the FDA regarding its dry eye treatment . Since Tuesday, th...
Johnson & Johnson-Protagonist Therapeutics Partnered New Psoriasis Pill Wins FDA Nod, Shakes Up Competition With AbbVie
FDA approves Icotyde, a once-daily psoriasis pill from Johnson & Johnson, sparking new competition in treatment options. ... Full story available on Benzinga.com
Glenmark Pharmaceuticals receives US FDA approval for Fluticasone Propionate Nasal Spray
Glenmark Pharmaceuticals Limited has announced that it has received final approval from the United States Food & Drug Administration (U.S. FDA) for its Fluticasone Propionate Nasal Spray USP, 50 mcg…